Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy
Author:
Publisher
Oxford University Press (OUP)
Subject
Immunology,General Medicine,Immunology and Allergy
Link
http://academic.oup.com/intimm/article-pdf/27/1/31/9723483/dxu089.pdf
Reference42 articles.
1. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
2. Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance
3. Allogeneic transplantation as anticancer immunotherapy
4. Rituximab
5. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells;Journal of Biomedical Science;2023-05-31
2. Approved Protein Therapeutics and Their Biochemical Targets;Protein-based Therapeutics;2023
3. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies;Current Opinion in Biotechnology;2022-12
4. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials;Journal of Clinical Pharmacy and Therapeutics;2022-07-29
5. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma;Cancer Letters;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3